Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
Year: 2014
Type: article
Source: Diabetes Care
DOI: 10.2337/dc14-1237
Authors: Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger, David Matthews, on behalf of the CANVAS Trial Collaborative Group
Institutions: The University of Sydney, The George Institute for Global Health, Royal Prince Alfred Hospital, The George Institute for Global Health, University Medical Center Groningen, University of Groningen, Stanford Medicine, Stanford University, Royal North Shore Hospital, Janssen Research & Development (United States), University of Oxford
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: GlaxoSmithKline, Servier
OpenAlex ID: W2141800817